Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project.

[1]  Y. Shin,et al.  MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  P. Stephens,et al.  Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  Yi-long Wu,et al.  The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  J. Pyo,et al.  Clinicopathological significance and concordance analysis of c-MET immunohistochemistry in non-small cell lung cancers: A meta-analysis. , 2016, Pathology, research and practice.

[5]  D. Costa,et al.  Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  Jeffrey W. Clark,et al.  Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC). , 2016 .

[7]  Shellaine R. Frazier,et al.  Interobserver reproducibility for HER2/neu immunohistochemistry: A comparison of reproducibility for the HercepTest™ and the 4B5 antibody clone. , 2016, Pathology, research and practice.

[8]  T. Mok,et al.  MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non–Small Cell Lung Carcinoma with Poor Prognosis , 2016, Clinical Cancer Research.

[9]  P. Jänne,et al.  MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Kobayashi,et al.  Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. , 2015, Lung cancer.

[11]  H. Sugimura,et al.  Clinicopathological and Survival Analysis of Japanese Patients with Resected Non–Small-Cell Lung Cancer Harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1, or PIK3CA Gene Amplification , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  S. Serrano,et al.  MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC) , 2015, Oncotarget.

[13]  N. Schultz,et al.  Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. , 2015, Cancer discovery.

[14]  J. Schiller,et al.  Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met-Amplified Adenocarcinoma of the Lung. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  F. Cappuzzo,et al.  Onartuzumab in lung cancer: the fall of Icarus? , 2015, Expert review of anticancer therapy.

[16]  T. Zander,et al.  MET Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the Lung , 2014, Clinical Cancer Research.

[17]  A. Marchetti,et al.  Lungscape: Resected Non–Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  Helen M. Moore,et al.  A review of preanalytical factors affecting molecular, protein, and morphological analysis of formalin-fixed, paraffin-embedded (FFPE) tissue: how well do you know your FFPE specimen? , 2014, Archives of pathology & laboratory medicine.

[19]  C. Dooms,et al.  Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  K. Nishio,et al.  Targeting MET Amplification as a New Oncogenic Driver , 2014, Cancers.

[21]  A. Iafrate,et al.  Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). , 2014 .

[22]  R. Tubbs,et al.  High MET Receptor Expression But Not Gene Amplification in ALK 2p23 Rearrangement Positive Non–Small-Cell Lung Cancer , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  Bruce E Johnson,et al.  The Introduction of Systematic Genomic Testing for Patients with Non–Small-Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  S. Peters,et al.  MET: a promising anticancer therapeutic target , 2012, Nature Reviews Clinical Oncology.

[25]  W. Pao,et al.  Chipping away at the lung cancer genome , 2012, Nature Medicine.

[26]  P. Ma,et al.  MET signaling: novel targeted inhibition and its clinical development in lung cancer. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[27]  T. Kohno,et al.  c-MET/Phospho-MET Protein Expression and MET Gene Copy Number in Non-small Cell Lung Carcinomas , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[28]  F. Hirsch,et al.  Correlation between MET Gene Copy Number by Silver In Situ Hybridization and Protein Expression by Immunohistochemistry in Non-small Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  Carmen Birchmeier,et al.  Targeting MET in cancer: rationale and progress , 2012, Nature Reviews Cancer.

[30]  R. Govindan,et al.  Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  R. Tishler,et al.  Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. , 2011, The Lancet. Oncology.

[32]  N. Girard,et al.  New driver mutations in non-small-cell lung cancer. , 2011, The Lancet. Oncology.

[33]  Y. Jeon,et al.  High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[34]  Luca Toschi,et al.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. , 2010, Cancer cell.

[35]  A. Marchetti,et al.  Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  J. Rüschoff,et al.  Proficiency testing of immunohistochemical biomarker assays in breast cancer , 2008, Virchows Archiv.

[37]  P. Jänne,et al.  Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.

[38]  J. R. Reeves,et al.  Evaluating HER2 amplification and overexpression in breast cancer , 2001, The Journal of pathology.

[39]  Jacques Ferlay,et al.  Estimating the world cancer burden: Globocan 2000 , 2001, International journal of cancer.

[40]  A. Chott,et al.  Effect of formalin tissue fixation and processing on immunohistochemistry. , 2000, The American journal of surgical pathology.

[41]  S. O'toole,et al.  Alterations of MET Gene Copy Number and Protein Expression in Primary Non-Small-Cell Lung Cancer and Corresponding Nodal Metastases. , 2016, Clinical lung cancer.

[42]  E. Do,et al.  Detection of ALK Gene Rearrangements in Formalin-Fixed, Paraffin-Embedded Tissue Using a Fluorescence In Situ Hybridization (FISH) Probe , 2012, Molecular Diagnosis.